Oura is preparing to go public on Nasdaq as it pushes beyond its smart ring hardware into AI-powered health guidance, leveraging biometric data streams to fuel subscription services with high margins and multiple new use cases in women’s health and connected care.
- Oura grew revenue 74% to $1.21B in nine months ending June 2026.
- Subscription revenue surged 121%, driving a near doubling of paid memberships to 5.7M.
- Proprietary AI models enhance personalized insights, particularly in women’s health.
Market signal
Oura’s Nasdaq IPO signals a significant market shift in wearable technology from purely device-focused offerings to comprehensive AI-driven health management platforms. The company’s ability to convert biometric data from its smart rings into actionable insights and personalized guidance showcases a matured value proposition that attracts subscription revenue with high gross margins.
The company targets a valuation above $15 billion, reflecting investor optimism in the scalable recurring revenue model supported by AI enhancements. The ramp-up in memberships to an estimated 5.7 million paid customers demonstrates market acceptance of AI-augmented health services integrated with biometric data captured continuously by wearable sensors.
Operator impact
For operators and buyers in the healthcare and wellness sectors, Oura’s approach emphasizes the importance of owning the data pipeline end-to-end—from signal capture in hardware to AI-powered interpretation within a fully controlled infrastructure. This operational model assures privacy and clinical validation while enabling tailored insights without imposing diagnostic claims.
Industry players working at the intersection of wearables, AI, and health data will need to balance hardware innovation with advanced software capabilities to maintain competitive differentiation. Oura’s focus on domains like women’s health and stress monitoring exemplifies niche vertical specialization, which could inspire operators to develop or partner on similar targeted AI applications embedded in consumer devices.
What to watch next
Key developments to monitor include Oura’s ability to scale its AI models beyond initial women’s health offerings and integrate broader biometric signals in other health areas. The company’s progress in refining its chatbot-driven health assistant, particularly user engagement and satisfaction metrics, will be clear indicators of commercial viability and product-market fit for AI-enhanced health guidance.
Competition will intensify as established tech and wearable brands like Samsung, Apple, and Whoop expand into hormone tracking, blood testing, and connected care partnerships. Attention should also focus on regulatory environments and data privacy frameworks shaping AI healthcare applications to assess operational risks and compliance requirements for providers embedding AI into consumer health ecosystems.